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roponin T and Peak Cardiac
roponin T Values Differ in Their
rognostic Properties
We read with interest the study by
assan et al1 investigating the ability of
eak cardiac troponin T (cTnT) to predict
nfarct size and long-term outcomes after
T elevation myocardial infarctions in pa-
ients treated with primary percutaneous
oronary intervention (PCI). Although we
o not disagree with the investigators’
onclusion that peak cTnT carries sub-
tantial predictive value regarding long-
erm outcome and infarct size, we would
ike to comment on several points.
We felt that the article lacked a clear
rticulation of the distinction between
TnT measured before primary PCI
i.e., usually at admission) and after pri-
ary PCI. It is well established that
TnT measured almost at any time point
fter PCI conveys powerful prognostic
nformation regarding impaired left
entricular function and infarct size.2,3
lthough admission cTnT is a predictor
f long-term mortality, which appears
rincipally related to the longer delay
nd recent myocardial damage,4 the as-
ociation of admission cTnT and infarct
ize is weak at best,4 and several studies
ave found no such relation.3,5
It is unfortunate, therefore, that in
onducting their analyses, Hassan et al1
ppear to have mixed pre- and post-PCI
amples of cTnT (given that 2% of the
tudy population were reported to have
ttained peak cTnT values before PCI).
t is likely that the inclusion of pre-PCI
amples in this report weakened the cor-
elations, although the impact was prob-
bly minor given the small fraction ofeak cTnT values originating from pre-
CI sampling.
To confuse matters further, in the dis-
ussion section, Hassan et al1 cite 4
revious studies as having measured peak
TnT, when in fact closer scrutiny of the
eports in question reveals that they all
easured admission cTnT values,6–9
hich makes comparison with the present
tudy unhelpful at best.
Last, Hassan et al1 conclude their re-
ort by advocating the use of serial cTnT
easurements to derive a peak value for
ptimal risk stratification after ST eleva-
ion myocardial infarction. Several recent
nvestigations have suggested that the
rognostic capacity of single-point cTnT
easurements, which would constitute a
uch easier strategy, is comparable with
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-Blocker Use and the Development
f Depression
We read with interest the report by
apademetriou1 in which the investiga-
or reported the effects of nebivolol for
he treatment of hypertension in a sam-
le of 845 subjects. Papademetriou ob-
erved that depression was not men-
ioned as an adverse event by subjects
eceiving nebivolol and used this obser-
ation to underline its favorable tolera-
ility. However, we disagree with his
uggestion that depression is a typical
omplaint related to -blocker use. This
s based on old research, often using
uestionable study designs.
Ko et al2 clearly demonstrated that
epression is not more often mentioned
s a side effect after  blockade than
fter placebo treatment. Using standard-
zed methods of depression, we also
ound no significant associations between
he use of  blockers and the develop-
ent of depression during the first year
fter myocardial infarction.3 After adjust-
ent for baseline depression, -blocker
sers even had somewhat lower depres-
ion scores than non--blocker users at 3
onths after myocardial infarction (p 
.06). Despite some old case reports, no












































































































1332 The American Journal of Cardiology (www.AJConline.org)epression is a common side effect of 
lockade. Unfortunately, this believe
nce again proves difficult to correct, and
n unfortunate side effect of that belief
ight be a continued reluctance in pre-
cribing  blockers for reasons of puta-
ive but unsupported depressant effects.
Joost P. van Melle, PhD, MD
Peter de Jonge, PhD
Groningen, The Netherlands
13 February 2009
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he Clinical Dilemma of Positive
esults of High-Sensitive Troponin
ssays
Since the widespread introduction of
ighly sensitive assays for troponin test-
ng,1–3 it is likely that the number of
atients presenting with values exceed-
ng the limit of detection and the rec-
mmended threshold corresponding to
ptimal precision (coefficient of varia-
ion 10%) will increase further, thus
aising a dilemma in the appropriate tri-
ge of these patients. According to the
niversal definition of acute myocar-
ial infarction (AMI), elevated value
igher than the decision level is re-
uired to establish the diagnosis of
MI.4 However, the demonstration of
n increasing and/or decreasing pattern
as also clearly highlighted, to help
istinguish background elevated tropo-
in levels (e.g., patients with chronic
enal failure) from elevations in the
ame patients that indicate AMI.4 These
ndications are strongly supported by
he recent findings of Eggers et al,5 who
howed that 0.6% of elderly subjects
rom a community sample and 6.7% of
atients stabilized after acute coronary
yndromes would have been labeled has
aving AMIs according to the universal
efinition of AMI when diagnostic clas-ification had been based on a single
ardiac troponin result.5 In line with the
ormer recommendations,4 the investi-
ators also supported the introduction
f a degree of troponin change 20%
s a diagnostic criterion, which would
robably be more appropriate to avoid
iagnostic misclassification. Although
his conceivably reflects the best prac-
ice so far, it raises a further dilemma
oncerning the appropriate triage of pa-
ients presenting with troponin values
lightly higher than the diagnostic
hreshold in the period between the first
nd the second troponin results, which
an be as long as 6 to 9 hours. It is
idely acknowledged that time is criti-
al for patients with AMIs, because the
linical outcome is strongly influenced
y the early onset of therapy, either
harmacologic or based on percutane-
us or surgical revascularisation.6 Pri-
ary percutaneous coronary interven-
ion, for example, appears to be more
ffective if vessel patency is restored
ithin 120 minutes,7 whereas anticoag-
lant or antiplatelet drugs should be ini-
iated as soon as possible to result in
ignificant clinical benefits.8
The enhanced sensitivity of the newer
roponin assays will inevitably determine
ubstantial increases in case identifica-
ion, so that physicians will face the new
hallenge of discriminating between pa-
ients who will benefit from more aggres-
ive treatment and those who will not,
ntil AMI is definitely diagnosed or ruled
ut. Highly sensitive troponin assays offer
reat diagnostic and clinical opportuni-
ies, but guidelines or recommendations
re urgently needed for the most appro-
riate management of patients and to limit
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1. In Table 2, the p values have been
transcribed incorrectly. The cor-






ntracranial bleed 0 0 N/A
etroperitoneal bleed 0 0 N/A
seudoaneurysm 1 (1) 5 (6) 0.119
Complicated
pseudoaneurysm:
0 5 (6) 0.029
rterio-venous fistula 0 0 N/A
ematoma 6 (7) 6 (7) 0.882
Transfusion-requiring 0 2 (2) 0.172hematoma
